Preferred Label : Avelumab;
NCIt synonyms : Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1,
pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody;
NCIt definition : A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive
ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint
inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1
and prevents the interaction of PD-L1 with its receptor programmed cell death protein
1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways.
This may restore immune function through the activation of cytotoxic T-lymphocytes
(CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces
an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing
tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily
expressed on T-cells, negatively regulates T-cell activation and effector function
when activated by its ligand, and plays an important role in tumor evasion from host
immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell
types and is associated with poor prognosis.;
UNII : KXG2PJ551I;
CAS number : 1537032-82-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1537032-82-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Bavencio;
Molecule name : MSB-0010718C;
Codes from synonyms : 53;
Origin ID : C116870;
UMLS CUI : C4055417;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
